Pathstone Holdings LLC Has $18.93 Million Stock Position in Stryker Co. (NYSE:SYK)

Pathstone Holdings LLC lessened its stake in shares of Stryker Co. (NYSE:SYK) by 0.1% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 52,392 shares of the medical technology company’s stock after selling 48 shares during the period. Pathstone Holdings LLC’s holdings in Stryker were worth $18,933,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Bessemer Group Inc. boosted its stake in Stryker by 100.4% in the 1st quarter. Bessemer Group Inc. now owns 18,267 shares of the medical technology company’s stock worth $6,538,000 after purchasing an additional 9,150 shares during the period. CreativeOne Wealth LLC boosted its position in shares of Stryker by 55.7% in the first quarter. CreativeOne Wealth LLC now owns 1,924 shares of the medical technology company’s stock worth $688,000 after buying an additional 688 shares during the period. EP Wealth Advisors LLC grew its holdings in shares of Stryker by 2.2% during the first quarter. EP Wealth Advisors LLC now owns 184,807 shares of the medical technology company’s stock valued at $66,137,000 after buying an additional 3,992 shares in the last quarter. Axxcess Wealth Management LLC raised its position in Stryker by 2.9% during the first quarter. Axxcess Wealth Management LLC now owns 5,074 shares of the medical technology company’s stock valued at $1,816,000 after buying an additional 143 shares during the period. Finally, Advisors Asset Management Inc. lifted its stake in Stryker by 14.7% in the 1st quarter. Advisors Asset Management Inc. now owns 25,943 shares of the medical technology company’s stock worth $9,284,000 after acquiring an additional 3,321 shares in the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Price Performance

Shares of Stryker stock opened at $388.66 on Wednesday. The company has a current ratio of 1.91, a quick ratio of 1.22 and a debt-to-equity ratio of 0.66. The firm has a fifty day simple moving average of $365.08 and a 200-day simple moving average of $348.40. The stock has a market capitalization of $148.16 billion, a price-to-earnings ratio of 41.66, a PEG ratio of 2.94 and a beta of 0.91. Stryker Co. has a 1-year low of $285.79 and a 1-year high of $398.20.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.10. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The firm had revenue of $5.49 billion during the quarter, compared to analyst estimates of $5.37 billion. During the same quarter in the previous year, the business earned $2.46 EPS. The business’s revenue was up 11.9% on a year-over-year basis. On average, sell-side analysts expect that Stryker Co. will post 12.06 earnings per share for the current year.

Insider Buying and Selling

In other news, VP M Kathryn Fink sold 7,347 shares of the company’s stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $366.98, for a total transaction of $2,696,202.06. Following the completion of the transaction, the vice president now directly owns 10,042 shares in the company, valued at $3,685,213.16. The trade was a 42.25 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Viju Menon sold 600 shares of the stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total value of $213,000.00. Following the completion of the sale, the insider now directly owns 9,069 shares of the company’s stock, valued at $3,219,495. This represents a 6.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 67,381 shares of company stock valued at $24,825,275. Insiders own 5.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. StockNews.com raised Stryker from a “hold” rating to a “buy” rating in a research note on Thursday, November 14th. BTIG Research upped their price objective on shares of Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. Barclays lifted their target price on shares of Stryker from $402.00 to $418.00 and gave the company an “overweight” rating in a research note on Thursday, October 31st. Citigroup upped their price target on shares of Stryker from $406.00 to $411.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Finally, Canaccord Genuity Group lifted their price objective on Stryker from $360.00 to $400.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Four investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $393.65.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.